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Cryptococcal meningitis: improving access to essential 
antifungal medicines in resource-poor countries
Angela Loyse*, *Harry Thangaraj*, Philippa Easterbrook, Nathan Ford, Monika Roy, Tom Chiller, Nelesh Govender, Thomas S Harrison, Tihana Bicanic
Cryptococcal meningitis is the leading cause of adult meningitis in sub-Saharan Africa, and contributes up to 20% of 
AIDS-related mortality in low-income and middle-income countries every year. Antifungal treatment for cryptococcal 
meningitis relies on three old, oﬀ -patent antifungal drugs: amphotericin B deoxycholate, ﬂ ucytosine, and ﬂ uconazole. 
Widely accepted treatment guidelines recommend amphotericin B and ﬂ ucytosine as ﬁ rst-line induction treatment for 
cryptococcal meningitis. However, ﬂ ucytosine is unavailable in Africa and most of Asia, and safe amphotericin B 
administration requires patient hospitalisation and careful laboratory monitoring to identify and treat common side-
eﬀ ects. Therefore, ﬂ uconazole monotherapy is widely used in low-income and middle-income countries for induction 
therapy, but treatment is associated with signiﬁ cantly increased rates of mortality. We review the antifungal drugs used 
to treat cryptococcal meningitis with respect to clinical eﬀ ectiveness and access issues speciﬁ c to low-income and 
middle-income countries. Each drug poses unique access challenges: amphotericin B through cost, toxic eﬀ ects, and 
insuﬃ  ciently coordinated distribution; ﬂ ucytosine through cost and scarcity of registration; and ﬂ uconazole through 
challenges in maintenance of local stocks—eg, sustainability of donations or insuﬃ  cient generic supplies. We advocate 
ten steps that need to be taken to improve access to safe and eﬀ ective antifungal therapy for cryptococcal meningitis.
Introduction
The right to health is ﬁ rmly established in international 
human rights law, and encompasses the right to ad-
equate access to health care and essential medicines.1–4 
Unfortunately, people in low-income and middle-income 
countries continue to face large barriers to the access of 
essential medicines, often with devastating consequences 
to individuals and public health. Essential medicines are 
the second largest family expenditure after food for the 
90% of the population in the developing world who have 
to purchase medicines privately.5 Barriers to access 
include drug expense, paucity of research and develop-
ment on diseases predominantly aﬀ ecting low-income 
and middle-income countries, insuﬃ  cient competition 
from generic manufacturers, inadequate drug procure-
ment and supply chains, and increasingly constrained 
global health funding.6–12
As a common opportunistic infection in patients 
with advanced HIV infection, cryptococcal meningitis is 
the leading cause of meningitis in adults living in 
sub-Saharan Africa, and contributes to up to 20% of AIDS-
related deaths every year in low-income and middle-income 
countries.13 Alth ough increased access to antiretroviral 
therapy has resulted in a substantial reduction in 
incidence of cryptococcal meningitis in high-income 
countries,14 the infection is likely to remain a major cause 
of HIV-related mortality in the foreseeable future in low-
income and middle-income countries, where antiretroviral 
ther apy coverage is insuﬃ  cient and initiated at an 
advanced stage of HIV. In addition to delays in the 
diagnosis and treatment of cryptococcal meningitis, poor 
access to essential antifungal medicines is a major 
contributor to this unacceptably high mortality. Although 
ﬂ uconazole monotherapy is associated with increased 
rates of mortality, inadequate access to alternative 
treatments means it is widely used in the treatment of 
cryptococcal meningitis.15 In this Personal View, we 
highlight the main obstacles to access of essential 
antifungal drugs for the treatment of cryptococcal 
meningitis in patients with HIV in low-income and 
middle-income countries. We review the three main 
antifungal drugs for cryptococcal meningitis—ampho-
tericin B, ﬂ ucytosine, and ﬂ uconazole—with re spect to 
clinical eﬀ ectiveness and access considerations speciﬁ c to 
low-income and middle-income countries, and suggest 
steps to improve access to safe and eﬀ ective antifungal 
treatment for cryptococcal meningitis.
Treatment of HIV-associated cryptococcal 
meningitis
Both the 2010 Infectious Diseases Society of America 
(IDSA) and 2011 WHO rapid advice guidelines 
recommend amphotericin B and ﬂ ucytosine as ﬁ rst-line 
induction treatment for patients with cryptococcal 
meningitis, with alternative regimens tailored to 
individual clinical settings (table 1).16,17 For settings in 
which ﬂ ucytosine is unavailable, second-line induction 
treatment consists of amphotericin B and high-dose 
(800–1200 mg per day) ﬂ uconazole.16,17 Where 
amphotericin B is unavailable or cannot be safely given 
and moni tored, high-dose ﬂ uconazole and ﬂ ucytosine is 
recom mended.16,17 The initial 2 week induction treatment 
is followed by consolidation and maintenance phases of 
treatment with ﬂ uconazole.16–18
Amphotericin B
Amphotericin B was introduced in the 1950s to treat 
systemic mycoses.19 The drug has a broad antifungal 
range and only few reports of resistance have been 
documented.20 Additionally, amphotericin B is used to 
treat visceral leishmaniasis.21 Substantial and common 
side-eﬀ ects of conventional amphotericin B formulations 
are anaemia, hypokalaemia, hypomag nesaemia, and 
nephrotoxicity.22,23 These eﬀ ects are reversible upon 
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treatment termination,23 but are con cerning in settings 
where availability of blood transfusion and renal 
replacement treatment is scarce. The need for 
intravenous administration, monitoring of blood count 
and renal function, and perception of unmanageable 
toxic eﬀ ects frequently prevent the use of amphotericin B 
in poorly resourced and understaﬀ ed hospital settings. 
Fluid and sodium loading and pre-emptive potassium 
replacement can reduce the risk of nephrotoxicity, and 
make administration of amphotericin B in low-income 
and middle-income countries more feasible.24 WHO 
guidelines for the management of cryptococcal 
meningitis provide clear guidance on how to safely 
administer amphotericin B deoxycholate.16
Amphotericin B is the most rapidly acting fungicidal 
agent against Cryptococcus neoformans. On the basis 
of evidence from clinical trials,23,25–31 treatment guide-
lines for crypto coccal meningitis recommend 2 weeks 
of amphotericin B-based treatment as ﬁ rst-line 
treatment, where possible.16–18 A strategy of short-course 
(5–7 days) ampho tericin B was associated with rapid 
cryptococcal clearance in two African studies,28,31 
enabling substantial reductions in both cost and toxic 
eﬀ ects of induction treatment. Although prohibitively 
expensive for patients in low-income and middle-
income countries, liposomal formulations of 
amphotericin B allow the delivery of high doses of 
amphotericin B and seem to be at least as eﬀ ective and 
less nephrotoxic than conventional amphotericin B.32,33 
Bristol-Myers Squibb (USA) is the main manufacturer 
of amphotericin B as Fungizone. At least one US Food 
and Drug Administration (FDA)-approved therapeutic 
equivalent of amphotericin B is marketed in the USA 
by X-Gen Pharmaceuticals (USA).34
The cost of amphotericin B continues to be a barrier to 
access.35 Prices range from US$3·51 to $12·20 per 50 mg 
vial (table 2), which is equivalent to the cost of a daily 
dose for cryptococcal meningitis treatment for a 50 kg 
adult, dosed at 1 mg/kg per day. Implementation of 
amphotericin B is connected with further attendant costs 
of hospitalisation, intravenous administration, and 
monitoring of toxic eﬀ ects. Insuﬃ  cient registration of 
amphotericin B is a challenge in some African countries 
(table 3).37
In 2005, Bristol-Myers Squibb was lobbied for a reduction 
in the price of amphotericin B in South Africa by the AIDS 
Law Project on behalf of the Treatment Action Campaign. 
The Southern African HIV Clinicians Society attained a 
price reduction from ZAR 146 to ZAR 26 ($18–$3) per 
50 mg vial.35 This reduction made possible the expanded 
use of amphotericin B and a switch away from initial 
ﬂ uconazole monotherapy for cryptococcal meningitis 
treatment in South Africa. In a survey of 25 sentinel 
hospitals in South Africa, the use of amphotericin B for 
cryptococcal meningitis induction treatment increased 
substantially, from 34% in 2005 to 83% in 2010.38
Access to amphotericin B might be further restricted by 
uncoordinated funding, procurement, and distribution of 
the drug. In low-income and middle-income countries, 
amphotericin B is funded, procured, and distributed by 
diﬀ erent organisations, both governmental (President’s 
Emergency Plan for AIDS Relief, the Global Fund, 
UNITAID) and non-governmental (International Drug 
Purchase Facility, Doctors without Borders, and Clinton 
Health Access Initiative [CHAI]); therefore, coordination 
is not neces sarily at country or regional levels. For 
example, a 2006 collaborative CHAI–UNITAID paediatric 
HIV/AIDS programme donated essential paediatric 
Amphotericin B accessible, 
facilities for management of toxic 
eﬀ ects* available; ﬂ ucytosine 
accessible
Amphotericin B accessible; 
ﬂ ucytosine not accessible
Amphotericin B accessible, 
facilities for management of 
toxic eﬀ ects* restricted; 
ﬂ ucytosine not accessible
Amphotericin B not 
accessible; ﬂ ucytosine 
accessible
Amphotericin B not 
accessible, facilities for 
management of toxic 
eﬀ ects* not available; 
ﬂ ucytosine not accessible
2011 WHO rapid 
advice guidelines16
Amphotericin B (0·7-1·0 mg/kg per 
day) and ﬂ ucytosine (100 mg/kg 
per day)
Amphotericin B (0·7-1·0 mg/kg 
per day) and ﬂ uconazole 
(800 mg/day)
Amphotericin B (0·7-1·0 mg/
kg per day) for 5–7 days, and 
ﬂ uconazole (800 mg/day) for 
2 weeks
Fluconazole (1200 mg/day) 
and ﬂ ucytosine (100 mg/kg 
per day) for ≥2 weeks
Fluconazole (1200 mg/day) 
for ≥2 weeks
2010 Infectious 
Diseases Society of 
America 
guidelines17
Amphotericin B (0·7–1·0 mg/kg per 
day) and ﬂ ucytosine (100 mg/kg per 
day) or liposomal amphotericin B 
(3·0–4·0 mg/kg per day) or 
amphotericin B lipid complex 
(5·0 mg/kg per day) and ﬂ ucytosine 
(100 mg/kg per day)
Amphotericin B (0·7–1·0 mg/kg 
per day) or liposomal 
amphotericin B (3–4 mg/kg per 
day) or amphotericin B lipid 
complex (5 mg/kg per day) or 
amphotericin B plus ﬂ uconazole
·· Fluconazole (800–1200 mg/
day favoured) and ﬂ ucytosine 
(100 mg/kg per day) for 
6 weeks
Fluconazole (800–2000 mg/
day) for 10–12 weeks or 
ﬂ uconazole 1200 mg/day 
(favoured)
2007 South African 
HIV Clinician 
Society guidelines18
Not applicable: ﬂ ucytosine 
unavailable in South Africa
Intravenous amphotericin B 
(1·0 mg/kg per day) for 2 weeks 
(minimum 1 week)
Amphotericin B (1 mg/kg per 
day) for minimum 1 week
Not applicable: ﬂ ucytosine 
unavailable in South Africa
Transfer patient to centre 
where amphotericin B 
available; if not possible, 
ﬂ uconazole (800 mg/day) for 
4 weeks
All induction cryptococcal meningitis courses are for 2 weeks, unless stated. *Minimum package of prehydration, electrolyte replacement, and monitoring and management of toxic eﬀ ects are available in 
these s ettings.16
Table 1: Guidelines for the induction treatment of cryptococcal meningitis depending on accessibility to amphotericin B and ﬂ ucytosine
www.thelancet.com/infection   Published online June 2, 2013   http://dx.doi.org/10.1016/S1473-3099(13)70078-1 3
Personal View
medi cines, including amphotericin B, to national HIV 
treat ment programmes in more than 40 countries in 
Africa, Asia, and the Caribbean. Uptake of amphotericin 
B was low compared with other drugs, in part attributable 
to clinician unawareness of the need for, and inexperience 
in clinical use of amphotericin B in children (S Essajee, 
CHAI, personal communication).
Perceived unmanageable toxic eﬀ ects as a result of 
insuﬃ  cient local education and inadequate facilities for 
safe administration and monitoring are an important 
disincentive to clinician uptake of amphotericin B for 
adults with cryptococcal meningitis, even when use is 
recommended by guidelines. This situation causes a fall 
in demand, which might contribute to intermittent 
failures of supply chains (in both high-income and low-
income countries35). At least three diﬀ erent lipid-based 
formulations are marketed (table 4). The most widely used 
liposomal intravenous formulation is AmBisome  (Gilead 
Sciences, CA, USA), the patent of which has recently 
expired in several countries. Dosed at 3 mg/kg per day, it 
is substantially less nephrotoxic than amphotericin B, but 
is prohibitively expensive for low-income and middle-
income countries (2011 British National Formulary list 
price per 50 mg vial: $150 in the UK; CIMS list price 
$225 in India). A substantial reduction in price to $18 per 
50 mg vial was negotiated by WHO for their visceral 
leishmaniasis programme.39 An equivalent price was 
oﬀ ered by Gilead Sciences to the South African 
Government for treatment of patients with cryptococcal 
meningitis (N Geﬀ en, Treatment Action Campaign, 
personal communication), but was not accepted. Gilead 
recently donated 445 000 vials of AmBisome for use over 
5 years for the WHO visceral leishmaniasis programme.40 
Fungisome (Lifecare Innovations Ltd, India) a liposomal 
formulation of amphotericin B developed and trialled in 
India,41 has a maximum retail price of $122 per 50 mg vial 
for the local market (table 4). Therefore, cost remains an 
important barrier to a switch from con ventional to less 
toxic liposomal formulations of amphotericin B in low-
income and middle-income countries. Cheap in-house 
pre parations of amphotericin B lipid emulsions, with 
rates of nephrotoxicity com parable to liposomal formu-
lations, warrant further eﬃ  cacy studies in low-income and 
middle-income countries.42
So far, only intravenous formulations of amphotericin B 
have been licensed. New oral formulations of 
amphotericin B are in early stages of development as part 
of the drive to improve access to treatment for visceral 
leishmaniasis,43,44 and are being developed by a Canadian 
ﬁ rm iCoTherapeutics. Under the terms of a socially 
responsible licensing agreement from the University of 
For British National Formulary 
list prices see http://www.bnf.
org/bnf/index.htm
For CIMS Directory Online list 
price data for India see http://
www.mims.com/India
Buyer prices per 
50 mg vial (US$)
Supplier Information on supplier Supplier prices per 
50 mg vial (US$)
South Africa (Department of Health) 4·23 Mission for Essential 
Drugs and Supplies 
(MEDS), Kenya
Not-for-proﬁ t Christian organisation. Coverage: 
Kenya, Tanzania, Ethiopia, Sudan, and Democratic 
Republic of Congo. Headquarters in Nairobi.
3·51
Rwanda (Centrale d’achat des 
Médicaments Essentiels, Consommables 
et Equipements Médicaux du Rwanda)
4·65 Missionpharma 
(MISSION), Denmark
Supplies generic medicines, medical devices and 
equipment, and medical kits. Coverage: Africa, 
India, and China. Headquarters in Denmark.
6·35
Uganda (Uganda National Medical 
Store)
5·00 IDA Foundation, 
Netherlands
Leading not-for-proﬁ t supplier of pharmaceutical 
products.  Supplies 3000 diﬀ erent medicines and 
medical supplies to more than 100 countries 
worldwide. Headquarters in Netherlands.
7·86
Namibia (Namibia Ministry of Health 
and Social Services)
6·97 ·· ·· ··
Barbados Drug Service 5·27 ·· ·· ··
Guatemalan Oﬃ  ce of Contracting and 
Acquisitions
9·75 ·· ·· ··
Costa Rica Social Security 12·20 ·· ·· ··
Modiﬁ ed from Management Sciences for Health and World Health Organization,36 by permission of Management Sciences for Health.  
Table 2:  Price of amphotericin B for buyers in African and Caribbean countries
Flucytosine  (250 mg or 
500 mg capsules)
Amphotericin B (50 mg/vial injection)
Registered Availability (at 
supplier level)
Registered Availability (at 
supplier level)
Price per vial 
(US$)†
Swaziland No No ·· Yes 4·56 and 6·25
South Africa No No* Yes Yes 3·86 and 6·11
Uganda No No No Yes 11·15
Kenya No No Yes Yes 9·71 and 4·02
Ethiopia No No Yes No ··
Sudan No No Yes Yes 3·64
Democratic Republic of Congo No No Yes No ··
Guinea No No No No ··
Cameroon No No No No ··
Tanzania No No No No ··
Data collected November–December 2011. *Through Section 21 of the Medicines Act, which allows for an unregistered 
medicine to be used on a named-patient basis (price=$US 1·4 per 500 mg capsule). †Prices represent supplier prices. 
Modiﬁ ed from Milani and Ford,37 by permission of  South African Medical Journal.
Table 3:  Registration, availability, and price of ﬂ ucytosine and amphotericin B in ten African countries
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British Columbia who devised the initial formulation,45–49 
iCoTherapeutics are committed to ensuring access to 
these formulations for treatment of visceral leishmaniasis 
in some low-income and middle-income countries, while 
allowing the company to pursue more lucrative high-
income markets for treatment of fungal infections.43,44,50
Flucytosine
Flucytosine was created in 1957 as a potential antitumour 
agent, and ﬁ rst used to treat human candidiasis and 
cryptococcosis in 1968.51,52 Flucytosine exerts its antifungal 
activity through rapid conversion into 5-ﬂ uorouracil,51,53 
and is available in intravenous and oral formulations, 
marketed as Ancotil 2·5 g/250 ml solution for infusion 
and Ancobon (Meda Pharmaceuticals, France) 500 mg 
capsules. Flucytosine is always used in combination with 
other antifungals because resistance emerges rapidly to 
monotherapy. Side-eﬀ ects are mediated by 5-ﬂ uorouracil, 
and include gastrointestinal and bone marrow toxic 
eﬀ ects.53–56 Studies in low-income and middle-income 
countries have shown that oral ﬂ ucytosine can be used 
safely and eﬀ ectively without monitoring drug levels in 
settings in which complete blood count and renal function 
are monitored and dosing intervals are extended if renal 
impairment occurs.23,26,28,30 Flucytosine can be given 
nasogastrically in unconscious patients.25
The use of ﬂ ucytosine was originally restricted because 
of the drug’s toxic eﬀ ects at high doses (150 mg/kg per day); 
however, since the 1980s, clinical trials of cryptococcal 
meningitis with progressively shorter courses of ﬂ u-
cytosine at lower doses (100 mg/kg per day) have shown 
that ﬂ ucytosine can be used safely and eﬀ ectively in com-
bination with amphotericin B (0·7–1 mg/kg per day).25,26,29 
A trial in Vietnam showed an association between 
decreased mortality rates and treatment with ﬂ ucytosine 
and amphotericin B compared with treatment with 
amphotericin B alone.29 Therefore, 2 weeks of ampho-
tericin B plus ﬂ ucytosine remains the gold standard for 
induction treatment of cryptococcal meningitis. In low-
income and middle-income countries, where ampho-
tericin B treatment is not available or feasible, ﬂ ucytosine 
can be safely and eﬀ ectively paired with high-dose 
ﬂ uconazole (1200 mg/day),57–60 as recommended by IDSA 
and WHO guidelines.16,17 Despite these guideline 
recommendations, ﬂ ucytosine is not yet available in 
most of Asia and Africa (table 3). The main barriers to 
access to ﬂ ucytosine include absence of drug registration 
and generic drug manufacturing in low-income and 
middle-income countries. Flucytosine is not registered in 
any African country.35,37 Flucytosine was previously 
marketed by Roche in South Africa, but registration of 
the drug lapsed in 1996.35
Dosage Generic version suppliers (approved by 
US Food and Drug Administration)
Route of 
administration
Trial data 
available
Patent status, representative 
patents, or patent applications
Amphotericin B
Bristol-Myers Squibb 
(USA) Fungizone
0·7-1·0 mg/kg per 
day
X-Gen Pharmaceuticals (USA) Intravenous Phase 4 Oﬀ  patent
Lipid formulations of amphotericin B
Gilead Sciences (USA) 
AmBisome (liposomal 
formulation)
3 mg/kg per day ·· Intravenous Phase 4 Ambisome: patent expired, 
except possibly in the USA 
(patent number US5874104)
Lifecare Innovations Ltd 
(India) Fungisome
5 mg/kg per day ·· Intravenous Phase 4 Fungisome: patent cooperation 
treaty application 
WO2011045809. Indian patent 
oﬃ  ce application 1258/kol/09
Cephalon (UK) Abelcet 
(lipid complex 
formulation)
5 mg/kg per day ·· Intravenous Phase 4 ··
Flucytosine
Meda Pharmaceuticals 
(France) Ancobon
100 mg/kg/day 
(four divided 
doses)
Sigmapharm Laboratories LLC (USA) Oral (or 
nasogastrically or 
intravenous)
Phase 4 Oﬀ  patent
Fluconazole
Pﬁ zer (USA) Diﬂ ucan Variable 
depending on 
induction or 
maintenance 
phase (refer to 
treatment 
guidelines)
Glenmark Generics (USA) 
IVAX Sub TEVA Pharmaceuticals (USA) 
Mylan (USA) 
TEVA (Israel) 
Apotex (Canada) 
Anneal Pharmaceuticals (USA) 
Roxane (USA) 
Aurobindo Pharmaceuticals (India) 
Oral (or 
intravenous)
Phase 4 Oﬀ  patent
Data from US Food and Drug Administration.34
Table 4:  Formulations of antifungal drugs for cryptococcal meningitis
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For WHO Global Price Reporting 
Mechanism see http://apps.who.
int/hiv/amds/price/hdd/t
The local National Health Service trust tender price for 
oral ﬂ ucytosine is 85p ($1·33) per 500 mg tablet for 
Ancobon (L Whitney, St George’s Hospital Pharmacy, 
personal com muni cation), or $182 for a 50 kg adult with 
cryptococcal meningitis receiving 14 days of induction 
treatment. Conversely, generic oral ﬂ ucytosine, 
manufactured by Sigmapharm, and approved by the FDA 
in 2011, retails in the USA at $34 per 500 mg ﬂ ucytosine 
tablet (A Sheppard, IMS Health, personal communication) 
or $4760 per 14-day course. Although ﬂ ucytosine is a 
nucleotide analogue of simple chemical structure that has 
been oﬀ -patent for many years, there seems to be market 
failure because of insuﬃ  cient demand and supply. A 
sustained eﬀ ort is needed to make this key component of 
cryptococcal meningitis treatment more widely available 
in low-income and middle-income countries.
Fluconazole
Fluconazole has excellent bioavailability and cerebro-
spinal ﬂ uid (CSF) penetration and few adverse eﬀ ects.61,62 
The drug is available in intravenous formulation and is 
commonly given orally to treat cryptococcal meningitis. 
Clinical and mycological outcomes in trials of low-dose 
ﬂ uconazole monotherapy (200–400 mg/day) as induction 
treatment have been disappointing, with high mortality 
and prolonged time to CSF sterilisation.15,63,64 This slow 
fungal clearance can predispose to development of 
secondary drug resistance and cryptococcal immune 
reconstitution syndrome.65–67 Phase 2 studies30,68 with high-
dose ﬂ uconazole in com bination with amphotericin B 
yielded good mycological and clinical outcomes and, in a 
larger trial, no diﬀ erence in 2 week and 10 week mortality 
was evident between amphotericin B plus ﬂ uconazole 
800 mg/day and amphotericin B plus ﬂ ucytosine.29 
Therefore, WHO and IDSA guidelines recommend the 
use of amphotericin B with high-dose ﬂ uconazole as 
second-line induction antifungal regimens.16,17
Higher doses of ﬂ uconazole (800–1200 mg/day) as 
induction treatment are well tolerated and have faster 
rates of fungal clearance than a dose of 400 mg daily.69 
Clearance rates are further improved when ﬂ uconazole 
is combined with ﬂ ucytosine.57,58 WHO guidelines 
include high-dose ﬂ uconazole monotherapy as an 
induction treatment option (table 1), but only when 
amphotericin B and ﬂ ucytosine are unavailable.16
Fluconazole is also a cornerstone of consolidation and 
maintenance treatment of cryptococcal meningitis16–18 
with published guidelines recommending step-down to 
ﬂ uconazole after the initial 2 week induction to prevent 
recurrence of disease.16–18 Since 2012, ﬂ uconazole has also 
been used to treat early cryptococcal disease detected 
through cryptococcal antigen screening.70 Pre-emptive 
treatment of patients with a CD4 count less than or equal 
to 100 cells per μL and asymptomatic cryptococcal 
antigenaemia with ﬂ uconazole is being piloted in South 
Africa as a public health strategy to reduce death and 
morbidity caused by cryptococcal meningitis.67,71
Fluconazole is oﬀ  patent, generally widely available and 
cheap, and numerous generic versions have FDA approval 
(table 4, price range with WHO Global Price Reporting 
Mechanism: $0·08–$1·36 per day when dosed at 800 
mg36). Although cost has greatly restricted access to 
ﬂ uconazole in the past,72 availability has gradually 
improved through increased production by generic 
manufacturers. Since 2000, Pﬁ zer’s (NY, USA) Diﬂ ucan 
Partnership programme has provided free Diﬂ ucan to 
63 low-income and middle-income countries for the 
treatment of patients with cryptococcal meningitis and 
oesopha geal candidiasis (not for the pre-emptive treatment 
of cryptococcal antigenaemia) and is set to continue 
indeﬁ nitely (Diﬂ ucan Partnership programme, Pﬁ zer, 
personal communication). However, imple mentation of 
the programme varies: at teaching hospital pharmacies at 
investigators’ collaborating trial sites in South Africa (Cape 
Town, Pietermaritzburg, and Durban) and Uganda 
(Mbarara and Kampala), donated Diﬂ ucan is readily 
available, whereas in Malawi (Blantyre and Lilongwe), 
Zambia (Lusaka), Cameroon (Douala and Yaoundé), and 
Tan zania (Arusha), purchased generic ﬂ uconazole rather 
than donated Diﬂ ucan is in stock, attributable to the 
challenges of sustaining timely and streamlined ordering 
through the donation programme. Although free ﬂ u-
conazole has been crucial for the treatment of cryptococcal 
meningitis in Africa, increased availability of ﬂ uconazole 
by comparison with amphotericin B might have led to 
clinicians favouring ﬂ uconazole over amphotericin 
B-based induction treatment.73,74
Recommendations for improvement of access 
to antifungals
We propose ten measures to improve access to crypto-
coccal meningitis treatment (panel). Improved estimates 
of disease burden, building upon studies by the CDC,13 
either via national cryptococcal surveillance systems (eg, 
South African National Institute for Communicable 
Diseases)75 or through localised epidemiological studies, 
would help with drug forecasting, streamline ordering, 
and maximise the use of donations. Such data would 
allow estimates of market size for manufacturers to be 
made and allow competitive price negotiation.
The 2011 WHO rapid advice guidelines16,76 provide 
recommendations on antifungal regimens tailored to 
clinical settings (table 1), and oﬀ ers guidance on how to 
minimise toxic eﬀ ects and monitor amphotericin B,16–18 
so that increased access does not produce more harm 
than good. These recommendations need to be trans-
lated into country-speciﬁ c or region-speciﬁ c treatment 
guidelines,18 and implemented alongside capacity 
building measures to improve facilities for rapid 
diagnosis, monitoring of toxic eﬀ ects, and fast-track 
referral into antiretroviral therapy programmes.
In the WHO Model List of Essential Medicines,the core 
(the most eﬃ  cacious, safe and cost-eﬀ ective medicines 
for priority conditions for use in a basic health-care 
For the South African National 
Institute for Communicable 
Diseases see http://www.nicd.ac.za
For the Diﬂ ucan Partnership 
programme see http://www.
diﬂ ucanpartnership.com
For the WHO Model List of 
Essential Medicines see http://
www.who.int/medicines/
publications/essential
medicines/en/
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system) list includes only ﬂ uconazole, while amphotericin 
B and ﬂ ucytosine, despite their greater eﬀ ectiveness in 
treatment of cryptococcal meningitis, are on the 
complementary list. Amphotericin B and ﬂ ucytosine 
should be included in the core list and national essential 
medicine lists and exempted from import duties and 
taxes.5–11 Antifungal drugs should be registered in low-
income and middle-income countries, and a requirement 
to show bio equivalence, quality standards (ie, good 
manufacturing practice), and eﬀ ectiveness of new generic 
formulations should be included. In many low-income 
and middle-income countries, medicines regulatory 
authorities are hampered by insuﬃ  cient resources and 
human capacity. Successful registration of antifungal 
drugs might need support from experienced authorities 
such as the Medicines Control Council of South Africa, 
the FDA, or European Medicines Agency,77 or even the 
introduction of a pan-African reciprocal drug-approval 
process. In South Africa, eﬀ orts are underway for fast-
track registration of ﬂ ucytosine with the Medicines 
Control Council (C Chuma, Lighthouse Healthcare, 
personal communication).
Drug companies should include antifungals in 
corporate responsibility policies on HIV, and consider 
preferential pricing for low-income and middle-income 
countries. Increased competition through generation of 
generics is needed. Generic pharmaceutical manufac-
turers should be given incentives and manufacturing 
support to produce generic versions of ﬂ ucytosine for 
the low-income and middle-income country markets. 
South Africa is exploring the manufacture of cheaper 
generic ﬂ ucytosine at facilities contracted by GSK and 
Pﬁ zer in Bangladesh; a lengthy process that needs a full 
Medicines Control Council inspection (C Chuma, 
Lighthouse Healthcare, personal communication). 
Pooled procurement of anti fungals would increase 
availability and secure com petitive prices, through 
eﬀ ective coordination of regional governments, global 
health organisations and funders, and pharma ceutical 
companies and distributors.78 Drug funding and 
distribution could be integrated with existing anti-
retroviral therapy programmes to provide antifungals 
alongside antiretrovirals, antituberculous drugs, and 
co-trimoxazole.
The optimisation of antifungal regimens in mortality-
endpoint trials in low-income and middle-income 
countries is a driver for policy change. A multicentre 
African phase 3 trial (ISRCTN 45035509) is comparing 
standard with short-course amphotericin B-based regi-
mens and a purely oral combination (ie, ﬂ uconazole plus 
ﬂ ucytosine). Additionally, socially responsible licensing 
of intellectual property79 should apply to new antifungals 
or formulations made through research funded by the 
public or by foundations. To our knowledge, only one 
new long-acting azole-like compound is in development 
in a joint project between Viamet pharmaceuticals and 
the NIH Therapeutics for Rare and Neglected Diseases 
programme.80 The scarcity of drug development for 
cryptococcal meningitis is in stark contrast to the range 
of new drugs emerging from product-development 
partnerships for the treatment of malaria and tuber-
culosis,81 diseases that are associated with a comparable 
mortality burden to cryptococcal meningitis in sub-
Saharan Africa.13
The research and advisory group Policy Cures lists 
three criteria essential to classify a disease as neglected:81 
the disease must predominantly aﬀ ect people in low-
income countries; needs new, improved, or additional 
products; and suﬀ ers from market failure because of an 
insuﬃ  cient commercial market, resulting in insuﬃ  cient 
research and development by industry. Cryptococcal 
meningitis fulﬁ ls all of these criteria. Oﬃ  cial 
classiﬁ cation of cryptococcal meningitis as a neglected 
disease would help attract funding for drug development.
Conclusions
Although continued global scale-up of antiretroviral 
therapy and initiation before the CD4 count falls below 
350 cells per μL remains the most important long-term 
strategy to reduce the incidence of cryptococcal meningitis, 
the infection will remain a major cause of HIV-related 
morbidity and mortality, particularly in sub-Saharan Africa 
in the foreseeable future. Treatment for cryptococcal 
meningitis relies on three old, oﬀ -patent antifungal drugs, 
which each pose speciﬁ c access challenges for low-income 
and middle-income countries: amphotericin B through 
cost, toxic eﬀ ects, and insuﬃ  ciently coordinated 
distribution; ﬂ ucytosine through cost and insuﬃ  cient 
registration; and ﬂ uconazole through challenges to 
maintenance of local stocks, be it through sustainability of 
Panel: Ten measures to improve access to antifungal 
drugs for the treatment of cryptococcal meningitis
• Improve estimates of cryptococcal meningitis disease 
burden
• Ensure wider dissemination of best clinical practice
• Include all cryptococcal meningitis drugs on WHO core 
Essential Medicines List
• Register antifungals in low-income and middle-income 
countries
• Pooled procurement of antifungals
• Increase competition through generation of generics
• Ensure preferential pricing for low-income and 
middle-income countries by pharmaceutical companies
• Ensure socially responsible licensing of intellectual 
property for new antifungals or formulations developed 
by research organisations
• Optimise existing antifungal strategies in clinical trials in 
low-income and middle-income countries
• Stimulate research and development of novel 
antifungals by designation of cryptococcal meningitis as 
a neglected dis ease
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donations or insuﬃ  cient generic supplies. If patients with 
crypto coccal meningitis survive the acute disease and 
become established on antiretroviral therapy, long-term 
prog nosis is excellent.15 It is unacceptable that up to one 
half of patients with cryptococcal meningitis in low-income 
and middle-income countries do not survive to 10 weeks, 
and do not beneﬁ t from expansion of antiretroviral therapy 
programmes, partly because even the basic range of 
antifungal drugs is not available to them.
Access to the most eﬀ ective antifungal drugs for 
treatment of cryptococcal meningitis in developing 
countries needs to be urgently improved as part of the 
global response to the HIV pandemic. A concerted 
move away from the widely-practised ﬂ uconazole 
monotherapy, towards more eﬀ ective combination 
induction treatment regimens including amphotericin 
B or ﬂ ucytosine or both, is needed. A coordinated 
international eﬀ ort should involve relevant public and 
private organisations and we must learn from models 
with proven success in the implementation of access to 
medicines for other important global infectious 
diseases. Facilitated by WHO, a meeting of key 
stakeholders took place in March 2013 and has given 
rise to a concerted advocacy eﬀ ort to improve access to 
essential antifungals for cryptococcal meningitis.
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